My Pharma Reviews
By Salil Kallianpur
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Salil Kallianpur
Category: Management
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 0
Reviews: 0
Episodes: 64
Description
| Episode | Date |
|---|---|
|
Strategy Is Only Half the Brand Plan
|
Nov 10, 2026 |
|
Rented Innovation
|
Nov 02, 2026 |
|
Who Owns the Customer Beyond the Prescription?
|
Oct 25, 2026 |
|
Revenue Is Not (Always) the Story
|
Sep 26, 2026 |
|
The Faustian Bargain
|
Sep 21, 2026 |
|
Episode 6: When Does a Pharma Platform Become Real?
|
Sep 19, 2026 |
|
Episode 5: From Pharma Platform to Healthcare Platform?
|
Sep 18, 2026 |
|
Episode 4: The Platform Can’t Outrun Its Culture
|
Sep 17, 2026 |
|
Episode 3: The Platform Starts After the Deal
|
Sep 16, 2026 |
|
Episode 2: The Platform Checklist
|
Sep 15, 2026 |
|
Episode 1: The Platform Thesis
|
Sep 14, 2026 |
|
The 4-5% Ceiling
|
Sep 13, 2026 |
|
The GLP-1 Reckoning
|
Aug 10, 2026 |
|
US Tariffs on Generic Medicines
|
Jul 22, 2026 |
|
India's GLP-1 Shakeout Is Coming
|
Jul 20, 2026 |
|
The $300 Billion Super-Cliff
|
Jul 14, 2026 |
|
Dr. Reddy's Semaglutide Stall In The GLP-1 Race
|
Jul 12, 2026 |
|
The Culture Gap
|
Jul 09, 2026 |
|
Episode 10: Biology Is The Software
|
Jul 06, 2026 |
|
Episode 9: The Last Prescription
|
Jun 30, 2026 |
|
Episode 8: The Gatekeeper Who Is Leaving the Building
|
Jun 28, 2026 |
|
Episode 7: The Capital Allocation Crisis
|
Jun 27, 2026 |
|
Episode 6: The Talent That Got Away
|
Jun 26, 2026 |
|
Episode 5: The Day the Patent Fell
|
Jun 24, 2026 |
|
Episode 4: The Qualification Gap
|
Jun 23, 2026 |
|
Episode3: The Biologics Report Card
|
Jun 18, 2026 |
|
Episode 2: The Generics Trap
|
Jun 17, 2026 |
|
Episode 1: The Bio-Health Supercycle
|
Jun 15, 2026 |
|
One Country. Three Markets
|
Jun 10, 2026 |
|
India's CDMO Moment
|
Jun 09, 2026 |
|
Organisational Theatre
|
Jun 08, 2026 |
|
Follow the Money
|
Jun 06, 2026 |
|
The Fallacy of Size
|
Jun 05, 2026 |
|
The Great Indian Pharma Split
|
Jun 04, 2026 |
|
Sun Pharma's Billion-Dollar Bet
|
Jun 03, 2026 |
|
One Shot. Done.
|
Jun 02, 2026 |
|
The Wrong Scoreboard
|
Jun 01, 2026 |
|
AI Run Rates vs. Pharma Blockbusters
|
May 19, 2026 |
|
You Make the Drug. They Own the Patient
|
May 18, 2026 |
|
APIs, CDMOs, Biologics, and AI
|
May 17, 2026 |
|
Hard to Copy Is Easy to Value
|
May 16, 2026 |
|
The Indian-CEO Alpha
|
May 14, 2026 |
|
India’s Semaglutide Market Is A Red Ocean
|
May 12, 2026 |
|
Biocon At The Crossroads.
|
May 06, 2026 |
|
The Imagination Deficit
|
May 05, 2026 |
|
The Five Truths Reshaping Indian Pharma
|
May 04, 2026 |
|
The $45 Billion Lesson Indian Pharma Isn't Learning
|
May 02, 2026 |
|
Cheap Semaglutide, Costly Reputations
|
Apr 30, 2026 |
|
India-Specific Disease R&D
|
Apr 29, 2026 |
|
Sun Pharma’s Organon Deal
|
Apr 28, 2026 |
|
The Optimizer CEO's Trap
|
Apr 27, 2026 |
|
Character: The Last Human Edge in an AI World
|
Apr 25, 2026 |
|
The Comfort Trap of Indian Pharma
|
Apr 24, 2026 |
|
Europe’s Pharma Paradox
|
Apr 23, 2026 |
|
Regulation is the Moat, Not the Enemy
|
Apr 21, 2026 |
|
India's Pharma Miracle
|
Apr 20, 2026 |
|
From Field Force to Force Multipliers
|
Apr 17, 2026 |
|
The Risk Pharma Refuses to Model
|
Apr 16, 2026 |
|
Vas Narasimhan-Anthropic Appointment
|
Apr 15, 2026 |
|
Healthcare’s Power Shift
|
Apr 14, 2026 |
|
10,000 Hours - What It Means for Pharma
|
Apr 13, 2026 |
|
The Next Pharma Gold Rush
|
Apr 12, 2026 |
|
Who Will Reinvent Indian Pharma?
|
Apr 09, 2026 |
|
China Just Connected Every Wearable Device to Its Health System
|
Apr 06, 2026 |